ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1573

Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis

Jomana mazareeb1, shiri keret1, Abid Awisat1, Itzhak Rosner2, Michel Rozenbaum3, Lisa Kaly1, Gleb Slobodin1 and Doron Rimar1, 1Bnai Zion Medical Center, Haifa, Israel, 2Bnai Zion Medical Center/Technion, Haifa, Israel, 3Bnei Zion Medical Center, Hertzeliya, Israel

Meeting: ACR Convergence 2022

Keywords: ANCA, Biomarkers, giant cell arteritis, Takayasu.s arteritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Vasculitis is an inflammation of blood vessels. While in many cases markers of inflammation as c- reactive protein (CRP) or erythrocytes sedimentation rate (ESR) may correlate with disease activity, in some cases inflammation markers are normal and evaluation of disease activity is based solely on clinical examination or imaging. Von – Willebrand factor (vWF) is a large multimeric glycoprotein, present in peripheral blood. It is produced constitutively as ultra-large VWF in endothelium and subendothelial connective tissue and is packed into storage organelles, the Weibel–Palade bodies (WPBs) on the surface of the endothelium. Damaged endothelium releases vWF. Sporadic reports have suggested vWF to be elevated in vasculitis.

The aim of our study is to evaluate vWF concentration in peripheral blood in patients with vasculitis as a marker of disease activity

Methods: Patients with systemic vasculitis diagnosed by tissue biopsy or typical imaging were classified according to Chapel hill consensus criteria and were evaluated. Demographic characteristics and clinical manifestations were assessed by frontal interview, physical examination and by medical records. Disease activity was reported by BVAS score. VWF was recorded at diagnosis and where available after treatment. vWF antigen was reported in % of predicted value and was adjusted to blood group (vWF level in patients with blood group o is normally reduced by 25% compared to other blood groups)

Results: Twenty-five patients with systemic vasculitis were compared to 15 healthy controls. There was no statistical difference between the two groups regarding age, 56 ± 17 years vs. 48±16 years or sex, females 56% vs. 50% (P=0.54). Forty percent had ANCA-associated vasculitis, 20% had Giant cell arteritis, 16% had polyarteritis nodosa, 8% had Takayasu and the rest had other vasculitides Time from diagnosis was 3.4±5 years. Mean vWF was higher in patients with active vasculitis compared to patients in remission and to healthy controls, 212%±81 vs. 159%±80 vs. 117%±35 p< 0.001 (figure 1) respectively. There was a direct correlation between vWF levels and BVAS score- r=0.31, p=0.04 (figure 2). In 10 patients with active vasculitis, who had a follow-up exam after treatment there was a significant decrease of vWF from 231%±61 to 169%±53 p< 0.02 (figure 3). There was no statistically significant correlation between CRP or ESR to BVAS score, yet CRP correlated directly with vWF r=0.32 p=0.07. In 4 patients who were treated with IL-6 inhibitors, vWF was elevated inspite of normal CRP levels, while clinically vasculitis was active.

Conclusion: This study demonstrates that vWF may be a possible biomarker for disease activity in patients with vasculitis. As vWF reflects direct damage to the endothelium and is not dependent on the IL-6 axis it is not confounded by IL-6 blockers, which are in wide use for vasculitis. Further studies should be undertaken to validate these preliminary findings.

Supporting image 1

graph 1, CRP, ESR and vWF values, in patients with vasculitis, 1A comparison between vWF in patients with active vasculitis, vasculitis patients in remission, and healthy controls. 1B CRP in patients with active vasculitis, vasculitis patients in remission. 1C ESR in patients with active vasculitis compared to vasculitis patients in remission

Supporting image 2

Correlation between disease activity according to BVAS and laboratory results. 3A correlation with vWF,

Supporting image 3

Follow up of vWF in 10 patients with vasculitis once diagnosed and 3-6 months after initiation of treatment.


Disclosures: J. mazareeb, None; s. keret, None; A. Awisat, None; I. Rosner, None; M. Rozenbaum, None; L. Kaly, None; G. Slobodin, None; D. Rimar, None.

To cite this abstract in AMA style:

mazareeb J, keret s, Awisat A, Rosner I, Rozenbaum M, Kaly L, Slobodin G, Rimar D. Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/von-willebrand-factor-a-possible-marker-for-disease-activity-in-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/von-willebrand-factor-a-possible-marker-for-disease-activity-in-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology